Wemade announced a strategic investment in DRX, a esports company
DRX IP to onboard WEMIX and expand its ecosystem
Both parties to cooperate for the advancement of eSports culture
SEOUL, South Korea, Dec. 1, 2022/PRNewswire/ -- Wemade announced a strategic investment in DRX. The companies will join forces in leading eSports fan culture and integrate it with the WEMIX platform for ecosystem expansion.
Founded in 2012, DRX is a Korean eSports company whose eSports teams include games such as League of Legend, Warcraft 3, Tekken 7 and more.
DRX's League of Legend team recently won the 2022 LoL World Championship, and Valorant team recorded 103 wins and 4 draws during a year and a half since its debut. With 22 championships under its belt, the team is considered to be the strongest in Asia.
Wemade plans to reach out to 3.7M DRX fans worldwide by onboarding DRX's excellent IP.
"eSports is a perfect fit for blockchain, since it has been evolving futuristically through repeated technical innovations," said Henry Chang, CEO of Wemade. "Through NILE, the DAO & NFT platform of WEMIX, we will complete a digital economy that connects gaming, entertainment, sports, art, and finance."
Wego, the largest online travel marketplace in the Middle East and North Africa (MENA), is thrilled to announce its continued partnership with the Tourism Authority of Thailand (TAT) for the fourth consecutive year, showcasing the unparalleled beauty...
ENOC Group, a leading integrated global energy player, has appointed the innovative technology loyalty partner, Loyyal, to integrate Access Point, their self-service platform, into the Group's rewards programme. This move will revolutionize the 'YES'...
Systal Technology Solutions, a global managed network, cloud, and security transformation specialist, today announces the opening of its new Network Operations Center (NOC) in Tampa, Florida. This marks the latest milestone in Systal's recent growth...
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...
ATTOM, a leading curator of land, property, and real estate data, today released its first-quarter 2024 U.S. Home Sales Report, which shows that profit margins on median-priced single-family home and condo sales in the United States decreased to 55.3...
